Sat May 24 17:14:03 UTC 2025: ## Indian Weight-Loss Market Buzzes with New Hormone-Mimicking Drug
**New Delhi, May 24, 2025:** The Indian weight-loss market is experiencing a surge of interest with the introduction of tirzepatide, marketed as Mounjaro by Eli Lilly. The drug, already approved in the U.S. for type 2 diabetes and obesity management, has been generating significant buzz since its recent approval and availability in India.
Endocrinologists like Dr. Anoop Misra report a high volume of inquiries, highlighting the anticipation surrounding these new “game changer” drugs. While Mounjaro comes with side effects like nausea and diarrhea, many Indians are willing to endure them for its potential weight-loss benefits. A single dose will cost between ₹3,500 and ₹4,375.
This new development is happening amidst a global obesity crisis, with the World Health Organization (WHO) reporting that one in eight people worldwide are living with obesity. Obesity is associated with a shortened life expectancy and an increased risk of various diseases.
The article discusses the impact on patients, like Aruna Lal, who have been in a decade-long battle with weight gain. Some patients report success with Mounjaro but also emphasize the importance of consulting endocrinologists, lifestyle changes, including exercise.
Experts like Dr. Pankaj Kumar Hans stress that these drugs are not suitable for everyone, and careful monitoring is crucial. The article also explores the growing market for weight-loss solutions in India, estimated at $25.2 billion in 2024 and projected to grow significantly.
The rising obesity rates and related health risks are also putting a strain on the Indian economy, with obesity costing India an estimated $28.95 billion in 2019. Experts emphasize the need for holistic approaches including lifestyle changes, healthy diets, and addressing the underlying environmental factors contributing to obesity.
First Piper 